Payment overview · 2025
General Payments
$1,148.34
14 reported records · 7 companies
Healthcare provider profile · identity verified
Collette Brown, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BRONX, NY · NPI 1932203239
Verified facts
What the public records show
CMS Open Payments records show Collette Brown, FNP received $1,148.34 in general payments during 2025 across 14 reported records.
Novo Nordisk Inc accounted for 34.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $395.14 | 34.4% | 5 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $167.65 | 14.6% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $149.50 | 13.0% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $125.38 | 10.9% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $125.00 | 10.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $123.93 | 10.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$61.74 | 5.4% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,148.34 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $265.02 | 3 | 2025 |
Source payment records
|
|||||
| PREVENA Normalized: prevena |
Device | Solventum Corporation | $167.65 | 2 | 2025 |
Source payment records
|
|||||
| Xolair Normalized: xolair |
Biological | Genentech USA, Inc. | $149.50 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $125.38 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $125.38 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $123.93 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $61.74 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $8.22 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $8.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 119 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 453 | 134 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 397 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 343 | 102 |
| Omeprazole | Omeprazole | 231 | 59 |
| Gabapentin | Gabapentin | 198 | 50 |
| Lisinopril | Lisinopril | 198 | 56 |
| Jardiance | Empagliflozin | 176 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 174 | 48 |
| Losartan Potassium | Losartan Potassium | 168 | 47 |
| Metformin Hcl | Metformin Hcl | 159 | 47 |
| Metformin Hcl Er | Metformin Hcl | 146 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 145 | 36 |
| Ozempic | Semaglutide | 119 | 23 |
| Levothyroxine Sodium | Levothyroxine Sodium | 118 | 24 |
| Famotidine | Famotidine | 114 | 37 |
| Eliquis | Apixaban | 105 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 101 | 23 |
| Montelukast Sodium | Montelukast Sodium | 100 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 32 |
| Nifedipine Er | Nifedipine | 88 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 87 | 31 |
| Farxiga | Dapagliflozin Propanediol | 83 | 17 |
| Mounjaro | Tirzepatide | 83 | 11 |
| Naproxen | Naproxen | 81 | 16 |
| Ammonium Lactate | Ammonium Lactate | 77 | 23 |
| Januvia | Sitagliptin Phosphate | 72 | 19 |
| Ibuprofen | Ibuprofen | 70 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 69 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 69 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | suppressed |
| Simvastatin | Simvastatin | 66 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 17 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 60 | 22 |
| Tramadol Hcl | Tramadol Hcl | 60 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | suppressed |
| Carvedilol | Carvedilol | 58 | 15 |
| Furosemide | Furosemide | 55 | 19 |
| Azelastine Hcl | Azelastine Hcl | 52 | 12 |
| Trulicity | Dulaglutide | 52 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 50 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 49 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 48 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 46 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 45 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 45 | 15 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 41 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 39 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 34 | suppressed |
| Ezetimibe | Ezetimibe | 34 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 12 |
| Alendronate Sodium | Alendronate Sodium | 31 | 13 |
| Ketoconazole | Ketoconazole | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Fluconazole | Fluconazole | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Prednisone | Prednisone | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Mupirocin | Mupirocin | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | 15 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 13 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 13 | suppressed |
| Flunisolide | Flunisolide | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Tivicay | Dolutegravir Sodium | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Vienva | Levonorgestrel/Ethin.Estradiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,148.34 · 14 records | Novo Nordisk Inc | ENTYVIO, MINIMED 780G, Nayzilam, OPSUMIT, Ozempic, PREVENA, Rybelsus, UPTRAVI, Wegovy, Xolair | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error